TRexBio: restoring tissue immune homeostasis via Treg modulation

TRexBio’s high-throughput system for target validation harnesses insights gained from regulatory T cell biology in human tissue to recreate disease-relevant pathways in vitro. The company is putting the platform to work in autoimmune and inflammatory diseases, including through two pharma deals. 

Because tissue-resident regulatory T cell (Treg) populations have different behaviors and phenotypes in mice than in humans, rooting drug discovery in human Treg biology is key, TRex Bio Inc. CSO Melanie Kleinschek told BioCentury. “The key for us is to use a systematic approach to study these cells in human tissues and find out how they are different and how we can use these insights to derive novel therapeutics for inflammatory diseases.”...